Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
Open Access
- 9 June 2021
- Vol. 13 (12), 2901
- https://doi.org/10.3390/cancers13122901
Abstract
Developing reliable experimental models that can predict clinical response before treating the patient is a high priority in gynecologic cancer research, especially in advanced or recurrent endometrial and ovarian cancers. Patient-derived organoids (PDOs) represent such an opportunity. Herein, we describe our successful creation of 43 tumor organoid cultures and nine adjacent normal tissue organoid cultures derived from patients with endometrial or ovarian cancer. From an initial set of 45 tumor tissues and seven ascites fluid samples harvested at surgery, 83% grew as organoids. Drug sensitivity testing and organoid cell viability assays were performed in 19 PDOs, a process that was accomplished within seven days of obtaining the initial surgical tumor sample. Sufficient numbers of cells were obtained to facilitate testing of the most commonly used agents for ovarian and endometrial cancer. The models reflected a range of sensitivity to platinum-containing chemotherapy as well as other relevant agents. One PDO from a patient treated prior to surgery with neoadjuvant trastuzumab successfully predicted the patient’s postoperative chemotherapy and trastuzumab resistance. In addition, the PDO drug sensitivity assay identified alternative treatment options that are currently used in the second-line setting. Our findings suggest that PDOs could be used as a preclinical platform for personalized cancer therapy for gynecologic cancer patients.Funding Information
- National Institutes of Health (R01CA099908, P30CA086862)
- U.S. Department of Defense (OC190352)
- National Center for Advancing Translational Sciences (UL1TR002537)
This publication has 48 references indexed in Scilit:
- Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicineCancer Discovery, 2017
- Chemoresistance and targeted therapies in ovarian and endometrial cancersOncotarget, 2016
- Clinical Behavior and Treatment of Endometrial CancerAdvances in Experimental Medicine and Biology, 2016
- A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during TumorigenesisCell Stem Cell, 2016
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialThe Lancet Oncology, 2015
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer PatientsCell, 2015
- USA Endometrial Cancer Projections to 2030: should we be concerned?Future Oncology, 2014
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerThe New England Journal of Medicine, 2006
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996